Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323:1945–60.

CAS  PubMed  Article  Google Scholar 

Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735–41.

CAS  PubMed  Article  Google Scholar 

Valaiyaduppu Subas S, Mishra V, Busa V, et al. Cardiovascular involvement in psoriasis, diagnosing subclinical atherosclerosis, effects of biological and non-biological therapy: a literature review. Cureus. 2020;12:e11173.

PubMed  PubMed Central  Google Scholar 

Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013;2:e000062.

PubMed  PubMed Central  Article  Google Scholar 

Kim BS, Lee WK, Pak K, et al. Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate-to-severe psoriasis: feasibility study using (18)F-fluorodeoxyglucose PET/CT. J Am Acad Dermatol. 2019;80:1322–31.

CAS  PubMed  Article  Google Scholar 

Gelfand JM, Shin DB, Alavi A, et al. A phase IV, randomized, double-blind, placebo-controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis (the VIP-U Trial). J Invest Dermatol. 2020;140:85–93.

CAS  PubMed  Article  Google Scholar 

Gelfand JM, Shin DB, Duffin KC, et al. A randomized placebo-controlled trial of secukinumab on aortic vascular inflammation in moderate-to-severe plaque psoriasis (VIP-S). J Invest Dermatol. 2020;140:1784–93.

CAS  PubMed  Article  Google Scholar 

Verhaar BJH, Prodan A, Nieuwdorp M, Muller M. Gut microbiota in hypertension and atherosclerosis: a review. Nutrients. 2020;12:2982.

CAS  PubMed Central  Article  PubMed  Google Scholar 

Zhou W, Cheng Y, Zhu P, Nasser MI, Zhang X, Zhao M. Implication of gut microbiota in cardiovascular diseases. Oxid Med Cell Longev. 2020;2020:5394096.

PubMed  PubMed Central  Google Scholar 

Nowinski A, Ufnal M. Trimethylamine N-oxide: a harmful, protective or diagnostic marker in lifestyle diseases? Nutrition. 2018;46:7–12.

CAS  PubMed  Article  Google Scholar 

Farhangi MA, Vajdi M, Asghari-Jafarabadi M. Gut microbiota-associated metabolite trimethylamine N-oxide and the risk of stroke: a systematic review and dose-response meta-analysis. Nutr J. 2020;19:76.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Buttner P, Okun JG, Hauke J, et al. Trimethylamine N-oxide in atrial fibrillation progression. Int J Cardiol Heart Vasc. 2020;29:100554.

PubMed  PubMed Central  Google Scholar 

Bin Waleed K, Lu Y, Liu Q, et al. Association of trimethylamine N-oxide with coronary atherosclerotic burden in patients with non-ST-segment elevation myocardial infarction. Medicine (Baltimore). 2020;99:e20794.

CAS  Article  Google Scholar 

Zhang Y, Wang Y, Ke B, Du J. TMAO: how gut microbiota contributes to heart failure. Transl Res. 2021;228:109–25.

CAS  PubMed  Article  Google Scholar 

Gregory JC, Buffa JA, Org E, et al. Transmission of atherosclerosis susceptibility with gut microbial transplantation. J Biol Chem. 2015;290:5647–60.

CAS  PubMed  Article  Google Scholar 

Sikora M, Chrabaszcz M, Maciejewski C, et al. Intestinal barrier integrity in patients with plaque psoriasis. J Dermatol. 2018;45:1468–70.

CAS  PubMed  Article  Google Scholar 

Sikora M, Chrabaszcz M, Waskiel-Burnat A, Rakowska A, Olszewska M, Rudnicka L. Claudin-3—a new intestinal integrity marker in patients with psoriasis: association with disease severity. J Eur Acad Dermatol Venereol. 2019;33:1907–12.

CAS  PubMed  Article  Google Scholar 

Sikora M, Stec A, Chrabaszcz M, et al. Intestinal fatty acid binding protein, a biomarker of intestinal barrier, is associated with severity of psoriasis. J Clin Med. 2019;8:1021.

CAS  PubMed Central  Article  PubMed  Google Scholar 

Hemann BA, Bimson WF, Taylor AJ. The Framingham Risk Score: an appraisal of its benefits and limitations. Am Heart Hosp J. 2007;5:91–6.

PubMed  Article  Google Scholar 

Collins GS, Altman DG. An independent and external validation of QRISK2 cardiovascular disease risk score: a prospective open cohort study. BMJ. 2010;340:c2442.

PubMed  PubMed Central  Article  Google Scholar 

Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S49-73.

PubMed  Article  Google Scholar 

Trzeciak B, Siebert J, Gutknecht P, Molisz A, Filipiak KJ, Wozakowska-Kaplon B. Cardiovascular risk factors determined via the Internet in 2 periods of time: 2004–2009 and 2010–2015 in Poland. Int J Occup Med Environ Health. 2017;30:499–510.

PubMed  Google Scholar 

Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297:611–9.

CAS  PubMed  Article  Google Scholar 

Jaworska K, Huc T, Samborowska E, et al. Hypertension in rats is associated with an increased permeability of the colon to TMA, a gut bacteria metabolite. PLoS ONE. 2017;12:e0189310.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Skrzypecki J, Izdebska J, Kaminska A, et al. Glaucoma patients have an increased level of trimethylamine, a toxic product of gut bacteria, in the aqueous humor: a pilot study. Int Ophthalmol. 2021;41:341–7.

PubMed  Article  Google Scholar 

Gelfand JM, Dommasch ED, Shin DB, et al. The risk of stroke in patients with psoriasis. J Invest Dermatol. 2009;129:2411–8.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Kimball AB, Robinson D Jr, Wu Y, et al. Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001–2002. Dermatology. 2008;217:27–37.

CAS  PubMed  Article  Google Scholar 

Rhee TM, Lee JH, Choi EK, et al. Increased risk of atrial fibrillation and thromboembolism in patients with severe psoriasis: a nationwide population-based study. Sci Rep. 2017;7:9973.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Sunbul M, Agirbasli M. Psoriasis and atherosclerosis: is there a need for novel biomarkers assessing cardiovascular risk? Curr Pharm Des. 2014;20:529–35.

CAS  PubMed  Article  Google Scholar 

Eder L, Gladman DD. Atherosclerosis in psoriatic disease: latest evidence and clinical implications. Ther Adv Musculoskelet Dis. 2015;7:187–95.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Puig L. Cardiometabolic comorbidities in psoriasis and psoriatic arthritis. Int J Mol Sci. 2017;19:58.

PubMed Central  Article  CAS  PubMed  Google Scholar 

Yeh CF, Chen YH, Liu SF, et al. Mutual interplay of host immune system and gut microbiota in the immunopathology of atherosclerosis. Int J Mol Sci. 2020;21:8729.

CAS  PubMed Central  Article  PubMed  Google Scholar 

Sikora M, Stec A, Chrabaszcz M, et al. Gut microbiome in psoriasis: an updated review. Pathogens. 2020;9:463.

CAS  PubMed Central  Article  PubMed  Google Scholar 

Romani J, Caixas A, Escote X, et al. Lipopolysaccharide-binding protein is increased in patients with psoriasis with metabolic syndrome, and correlates with C-reactive protein. Clin Exp Dermatol. 2013;38:81–4.

CAS  PubMed  Article  Google Scholar 

Ramirez-Bosca A, Navarro-Lopez V, Martinez-Andres A, et al. Identification of bacterial DNA in the peripheral blood of patients with active psoriasis. JAMA Dermatol. 2015;151:670–1.

PubMed  Article  Google Scholar 

Coras R, Kavanaugh A, Boyd T, et al. Choline metabolite, trimethylamine N-oxide (TMAO), is associated with inflammation in psoriatic arthritis. Clin Exp Rheumatol. 2019;37:481–4.

PubMed  PubMed Central  Google Scholar 

Duttaroy AK. Role of gut microbiota and their metabolites on atherosclerosis, hypertension and human blood platelet function: a review. Nutrients. 2021;13:144.

CAS  PubMed Central  Article  PubMed  Google Scholar 

Yang S, Li X, Yang F, et al. Gut microbiota-dependent marker TMAO in promoting cardiovascular disease: inflammation mechanism, clinical prognostic, and potential as a therapeutic target. Front Pharmacol. 2019;10:1360.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Boini KM, Hussain T, Li PL, Koka S. Trimethylamine-N-oxide instigates NLRP3 inflammasome activation and endothelial dysfunction. Cell Physiol Biochem. 2017;44:152–62.

PubMed  Article  Google Scholar 

Sun X, Jiao X, Ma Y, et al. Trimethylamine N-oxide induces inflammation and endothelial dysfunction in human umbilical vein endothelial cells via activating ROS-TXNIP-NLRP3 inflammasome. Biochem Biophys Res Commun. 2016;481:63–70.